Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03973801
Other study ID # 191023
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 19, 2019
Est. completion date September 16, 2019

Study information

Verified date March 2020
Source Vanderbilt University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the feasibility of implementing auricular acupressure as an additional non-pharmacologic therapy for neonates at risk for developing neonatal abstinence syndrome (NAS) at Monroe Carrell Jr Children's Hospital at Vanderbilt University Medical Center (VUMC).


Description:

NAS is a condition in which newborns experience withdrawal symptoms as a result of in utero exposure to opioids and/or other substances ingested by the mother. The condition has significantly risen over the past 20 years. First line treatments for NAS involve the maximization of non-pharmacologic therapies. NAS management focuses on reducing or eliminating the need for medication management to prevent further developmental complications, promote maternal bonding, and reduce hospital length of stay.

Auricular acupuncture has been used for the treatment of addiction and has demonstrated efficacy in the adult population. Current evidence suggests that acupuncture is safe and beneficial for multiple conditions that impact neonatal and pediatric populations including NAS. Acupressure is a less invasive therapy and may serve as an additional non-pharmacological adjunct to ease the severe discomfort of withdrawal in neonates at risk for NAS.

This study will assess the feasibility of implementing auricular acupressure as an additional non-pharmacologic therapy for neonates at risk for developing neonatal abstinence syndrome (NAS) at Monroe Carrell Jr Children's Hospital at Vanderbilt University Medical Center (VUMC).


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date September 16, 2019
Est. primary completion date September 16, 2019
Accepts healthy volunteers No
Gender All
Age group N/A to 24 Hours
Eligibility Inclusion Criteria:

- 37 weeks gestational age or greater

- Maternal age 16 or older

- Substance exposure in utero including opioids, illicit drugs, or other medications that cause neonatal withdrawal

Exclusion Criteria:

- Birth trauma

- Neonatal asphyxia

- Maternal or neonatal infection

- Congenital abnormalities

- Requiring Neonatal Intensive Care Unit (NICU) care

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Auricular acupuncture
National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.

Locations

Country Name City State
United States Vanderbilt University Medical Center Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Vanderbilt University Medical Center Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of eligible patients enrolled end of study enrollment (about 12 weeks)
Primary Percent of patients prematurely terminating treatment hospital discharge (about 48-72 hours after delivery)
Primary Percent of participants completing all study assessments hospital discharge (about 48-72 hours after delivery)
Primary Percent of data collection procedures completed hospital discharge (about 48-72 hours after delivery)
Primary Percent of missing medical record data hospital discharge (about 48-72 hours after delivery)
Secondary Percent of providers enrolled in 3 day training course for NADA protocol Prior to start of study enrollment (May 31, 2019)
Secondary Percent of providers completing 3 day training course for NADA protocol Percent of providers completing 3 day training course for NADA protocol: The training course includes a national, standardized curriculum, clinical demonstration and skills lab. Providers are trained in application of acupuncture needles which are placed at the same location as acupressure stickers. Day 3 of training
Secondary Percent of providers completing clinical competency with NADA protocol Percent of providers completing clinical competency with NADA protocol: Following the training course providers must submit pictures to the NADA instructor with a clinical log of 40 appropriately placed acupuncture needles in accordance with the NADA protocol. Training includes Prior to start of study enrollment (May 31, 2019)
Secondary Percent of providers receiving NADA certification Percent of providers receiving NADA certification: Once clinical practice is complete and verified by a NADA trainer, providers will receive a NADA certification Prior to start of study enrollment (May 31, 2019)
Secondary Percent of providers receiving credentialing Following certification of the providers, competency of acupressure placement on neonates for the specific study protocol will be demonstrated via simulation lab. Providers must perform the acupressure, in accordance with the NADA protocol, on a neonatal manikin, and documentation of the appropriate technique will be completed for credentialing purposes. Providers will submit the NADA certificate, a skills checklist that documents appropriate NADA technique on a neonate manikin, and a neonatal simulation lab certificate for credentialing to perform NADA protocol at VUMC. Prior to start of study enrollment (May 31, 2019)
Secondary Client Satisfaction Questionnaire (CSQ*) Score On day of discharge, the parent(s) will receive the Client Satisfaction Questionnaire (CSQ8) to assess parental satisfaction of acupuncture as an additional therapy. The CSQ8 is an 8 item measure of client satisfaction with services. Items are questions inquiring about respondents' opinions and conclusions about services they have received. Response options differ from item to item, but all are based on a four-point scale. The overall score is produced by summing all item responses. CSQ-8 version scores range from 8 to 32, with higher values indicating higher satisfaction. Day of discharge (about 48-72 hours after delivery)
Secondary Intervention Appropriateness Measure (IAM) Score Provider and staff acceptability of acupressure as an additional non-pharmacologic treatment will be measured with the Intervention Appropriateness Measure (IAM). The IAM is a four-item measure of the appropriateness of an intervention. Each item of the score is rated on a five point scale where 1 equals completely disagree and 5 equals completely agree. The total score ranges from 5 to 20, with a higher score indicating a higher level of appropriateness. Day of hospital discharge of baby (about 48-72 hours after delivery)
Secondary Acceptability of Intervention Measure (AIM) Provider and staff acceptability of acupressure as an additional non-pharmacologic treatment will be measured with the Acceptability of Intervention Measure (AIM). The AIM is a four-item measure of the acceptability of an intervention. Each item of the score is rated on a five point scale where 1 equals completely disagree and 5 equals completely agree. The total score ranges from 5 to 20, with a higher score indicating a higher level of acceptability. Day of hospital discharge of baby (about 48-72 hours after delivery)
Secondary Feasibility of Intervention Measure (FIM) Provider and staff acceptability of acupressure as an additional non-pharmacologic treatment will be measured with the Feasibility of Intervention Measure (FIM). The FIM is a four-item measure of the feasibility of an intervention. Each item of the score is rated on a five point scale where 1 equals completely disagree and 5 equals completely agree. The total score ranges from 5 to 20, with a higher score indicating a higher level of feasibility. Day of hospital discharge of baby (about 48-72 hours after delivery)
See also
  Status Clinical Trial Phase
Completed NCT01965704 - Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women Phase 2
Completed NCT03890562 - Assessing the Effects of Auricular Acupressure on Newborns With NAS N/A
Completed NCT01958476 - Improving Outcomes in Neonatal Abstinence Syndrome Phase 3
Active, not recruiting NCT01734551 - NAS Treatment - Opiate Versus Non-Opiate Phase 4
Completed NCT00496951 - Vagal Tone and Neonatal Abstinence Syndrome N/A
Completed NCT02851303 - Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Phase 4
Recruiting NCT05226624 - The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program N/A
Completed NCT03670160 - Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome Phase 2
Not yet recruiting NCT04611659 - Averting NAS Among Opioid-Using Young Women Receiving MAT Using Buprenorphine N/A
Completed NCT01452789 - Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome Phase 3
Completed NCT04588519 - tAN to Mitigate Withdrawal Behaviors in Neonates N/A
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Completed NCT02801331 - Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome N/A
Terminated NCT03246243 - Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk
Completed NCT03567603 - Sound Processing Changes in Babies With Opioid Exposure
Recruiting NCT06303986 - Study to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process
Active, not recruiting NCT03725332 - The PATH Home Trial: A Comparative Effectiveness Study of Peripartum Opioid Use Disorder in Rural Kentucky N/A
Recruiting NCT04983563 - Actigraphy and Neonatal Abstinence Syndrome of Hospitalized Newborn in Intensive Care Units N/A
Completed NCT04298853 - Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome Phase 4
Completed NCT02182973 - Donor Human Milk in Neonatal Abstinence Syndrome